Our top pick for
Caleres Inc is a footwear & accessories business based in the US. Caleres shares (CAL) are listed on the NYSE and all prices are listed in US Dollars. Caleres employs 4,900 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$22.15|
|52-week range||$7.46 - $29.27|
|50-day moving average||$23.17|
|200-day moving average||$24.37|
|Wall St. target price||$35.50|
|Dividend yield||$0.28 (1.22%)|
|Earnings per share (TTM)||$-0.57|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-06)||N/A|
|1 month (2021-09-17)||-0.45%|
|3 months (2021-07-16)||-3.44%|
|6 months (2021-04-16)||-7.13%|
|1 year (2020-10-16)||138.94%|
|2 years (2019-10-16)||2.50%|
|3 years (2018-10-16)||34.74|
|5 years (2016-10-14)||26.16|
Valuing Caleres stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Caleres's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Caleres's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.74. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Caleres's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Caleres's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $180 million.
The EBITDA is a measure of a Caleres's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$2.5 billion|
|Operating margin TTM||5.14%|
|Gross profit TTM||$824.4 million|
|Return on assets TTM||4.12%|
|Return on equity TTM||-7.18%|
|Market capitalisation||$847.6 million|
TTM: trailing 12 months
There are currently 2.7 million Caleres shares held short by investors – that's known as Caleres's "short interest". This figure is 5.1% up from 2.6 million last month.
There are a few different ways that this level of interest in shorting Caleres shares can be evaluated.
Caleres's "short interest ratio" (SIR) is the quantity of Caleres shares currently shorted divided by the average quantity of Caleres shares traded daily (recently around 670573). Caleres's SIR currently stands at 4. In other words for every 100,000 Caleres shares traded daily on the market, roughly 4000 shares are currently held short.
However Caleres's short interest can also be evaluated against the total number of Caleres shares, or, against the total number of tradable Caleres shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Caleres's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Caleres shares in existence, roughly 70 shares are currently held short) or 0.0733% of the tradable shares (for every 100,000 tradable Caleres shares, roughly 73 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Caleres.
Find out more about how you can short Caleres stock.
Dividend payout ratio: 9.69% of net profits
Recently Caleres has paid out, on average, around 9.69% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.26% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Caleres shareholders could enjoy a 1.26% return on their shares, in the form of dividend payments. In Caleres's case, that would currently equate to about $0.28 per share.
While Caleres's payout ratio might seem low, this can signify that Caleres is investing more in its future growth.
Caleres's most recent dividend payout was on 30 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 8 September 2021 (the "ex-dividend date").
Caleres's shares were split on a 3:2 basis on 2 April 2007. So if you had owned 2 shares the day before before the split, the next day you'd have owned 3 shares. This wouldn't directly have changed the overall worth of your Caleres shares – just the quantity. However, indirectly, the new 33.3% lower share price could have impacted the market appetite for Caleres shares which in turn could have impacted Caleres's share price.
Over the last 12 months, Caleres's shares have ranged in value from as little as $7.4598 up to $29.2674. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Caleres's is 2.6444. This would suggest that Caleres's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Caleres, Inc. engages in the retail and wholesale of footwear in the United States, China, Canada, China, and Guam. It operates through Famous Footwear and Brand Portfolio segments. The company offers licensed, branded, and private-label athletic, casual, and dress footwear products to women, men, and children. Its retail shoe stores provide brand name athletic, casual, and dress shoes, including Nike, Skechers, adidas, Vans, Converse, Crocs, Puma, Birkenstock, Asics, New Balance, Under Armour, Bearpaw, Timberland, and Sperry, as well as company-owned and licensed brands, such as Dr. Scholl's Shoes, Blowfish Malibu, LifeStride, Naturalizer, Circus by Sam Edelman, Franco Sarto, and Ryka. The company also operates naturalizer.
Everything we know about the TraQiQ IPO, plus information on how to buy in.
Everything we know about the AirSculpt Technologies IPO, plus information on how to buy in.
Everything we know about the Blackboxstocks IPO, plus information on how to buy in.
Everything we know about the The Very Good Food Company IPO, plus information on how to buy in.
Everything we know about the Tricon Residential IPO, plus information on how to buy in.
Everything we know about the Udemy IPO, plus information on how to buy in.
Everything we know about the Bluejay Diagnostics IPO, plus information on how to buy in.
Everything we know about the Solo Brands IPO, plus information on how to buy in.
Everything we know about the Arhaus IPO, plus information on how to buy in.
Everything we know about the GlobalFoundries IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.